Table 1 Demographic and clinical characteristics of patients
From: Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series
| Characteristic | Patients (N = 8) |
|---|---|
| Median age (IQR), years | 60.5 (47.5–68.5) |
| Male sex, no. (%) | 4 (50.0) |
| Oxygen support, no. (%) | 0 |
| Body mass index (kg/m2), median (IQR) | 22.2 (20.0–26.8) |
| Median duration of positive RNA detection before favipiravir therapy (days), median (IQR) | 61.0 (52.8–67.3) |
| Other therapies before favipiravir therapy, no. (%) | |
| Chloroquine phosphate | 4 (50.0) |
| Umifenovir | 3 (37.5) |
| Entecavir | 1 (12.5) |
| Lianhua Qingwen granules | 2 (25.0) |
| Thymopeptides | 4 (50.0) |
| Pidotimod | 4 (50.0) |
| Plasma transfusion | 2 (25.0) |
| Coexisting conditions, no. (%) | |
| Any condition | 6 (75.0) |
| Hypertension | 4 (50.0) |
| Diabetes | 2 (25.0) |
| Coronary heart disease | 1 (12.5) |
| Malignant tumor | 2 (25.0) |
| Immunoglobulin level (AU/mL), median (IQR) | |
| IgM | 12.5 (5.1–25.2) |
| IgG | 102.7 (56.1–162.5) |